Immunic Inc (IMUX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.32-7.81%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IMUX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
IMUX — litigation filed
Dated 2026-11-05
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchan g e Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements Certa…
Why it matters: These results test whether vidofludimus calcium helps people with relapsing MS. A clear benefit would support the lead drug's path forward.
Watch forBy December 31, 2026, Immunic reports that ENSURE met its main goal. The trial showed a clear benefit over placebo.
Also watch forImmunic reports that ENSURE missed its main goal, or gives no top-line results by December 31, 2026.
Why it matters: Starting this trial would extend the lead drug's testing into progressive MS. A delay would push back this part of the program.
Supportive ifBy December 31, 2026, Immunic announces that the first patient joined its Phase 3 trial for progressive MS. The trial aims to confirm earlier results.
Worry ifThe trial has not started by December 31, 2026, or Immunic announces a delay.
Why it matters: Immunic guided to a 2026 loss of $1.08 per share. A larger loss could add to funding pressure as trials continue.
Worry ifAt the November 12, 2026 earnings update, Immunic reports or guides to a 2026 loss per share greater than $1.08.
Less concerning ifAt the November 12, 2026 earnings update, Immunic keeps or lowers its 2026 forecast for loss per share of $1.08.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$258 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $768 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,059 loss on $10,000 · 60.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.